Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine + meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Tdap + MenACWY-CRM refers to the concomitant administration of a booster vaccine for tetanus, diphtheria, and pertussis (Tdap) and a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM). Tdap vaccines, such as **Boostrix** or **Adacel**, contain tetanus and diphtheria toxoids along with acellular pertussis antigens to provide active immunity against *Clostridium tetani*, *Corynebacterium diphtheriae*, and *Bordetella pertussis*. MenACWY-CRM, marketed as **Menveo**, consists of four meningococcal capsular oligosaccharides (serogroups A, C, Y, and W-135) individually conjugated to a non-toxic mutant of diphtheria toxin known as **CRM197**, which acts as a carrier protein to enhance the T-cell dependent immune response. This combination is typically administered to adolescents and young adults (ages 11-25) to provide broad protection against bacterial meningitis and respiratory infections. Clinical studies have demonstrated that co-administration does not compromise the immunogenicity or safety profile of either vaccine component.
- Other names
- Tdap + MenACWY-CRMTdap and MenACWY-CRM co-administrationConcomitant Tdap and MenACWY-CRM
02
Targets
FHA (Filamentous hemagglutinin)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideNeisseria meningitidis capsular polysaccharidePRN (Pertactin)Reduced diphtheria toxoidTT (Tetanus toxoid)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine + meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine + meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine.